# Modulation of Wnt/β‐Catenin Pathway by Aesculus hippocastanum Extract Enhances Temozolomide Sensitivity in Glioblastoma Cells

**Authors:** Sarah Adriana Scuderi, Alessio Ardizzone, Deborah Mannino, Nicoletta Palermo, Fabiola De Luca, Antonio Catalfamo, Michela Campolo, Emanuela Esposito, Irene Paterniti

PMC · DOI: 10.1111/jcmm.70979 · 2026-02-16

## TL;DR

Horse chestnut extract enhances the effectiveness of temozolomide in treating glioblastoma by targeting the Wnt/β-catenin pathway.

## Contribution

This study is the first to show that horse chestnut extract increases temozolomide sensitivity in glioblastoma cells via Wnt/β-catenin pathway modulation.

## Key findings

- Combined treatment with horse chestnut extract and temozolomide significantly reduced cell viability and inhibited wound healing and colony formation.
- The combination therapy downregulated β-catenin, Wnt-1, Nestin, and β3-tubulin, indicating reduced tumour stemness and aggressiveness.
- Apoptotic activity increased with combination treatment, supported by increased p53 expression and membrane permeability.

## Abstract

Glioblastoma (GB) is a highly aggressive brain tumour with a poor prognosis and limited responsiveness to standard chemotherapy, particularly temozolomide (TMZ), due to intrinsic resistance mechanisms. This study investigates the potential of 
Aesculus hippocastanum, known as horse chestnut extract (HCE), to enhance the therapeutic efficacy of TMZ in GB cells through modulation of the Wnt/β‐catenin signalling pathway. Combined treatment of HCE (500 μg/mL) and TMZ (100 μM) significantly reduced cell viability and inhibited wound healing and colony formation compared to either agent alone at 48 h. Notably, the expression of β‐catenin and Wnt‐1 was significantly reduced in the combination group, followed by a significant downregulation of Nestin and β3‐tubulin, markers of glioma stem‐like cells and aggressiveness, respectively. Furthermore, apoptotic activity was significantly increased following the combined treatment. In a 3D U87‐spheroid model, the combination therapy resulted in a substantial reduction in spheroid area, suggesting impaired tumour growth. Propidium iodide (PI) staining revealed increased membrane permeability in cells treated with the combination, which was accompanied by an increase in p53 expression, supporting the induction of apoptosis. Collectively, these findings demonstrate that HCE increases the cytotoxic effects of TMZ by inhibiting Wnt/β‐catenin signalling, reducing tumour stemness, and promoting apoptotic pathways in GB cells.

## Linked entities

- **Genes:** ctnnb1.S (catenin beta 1 S homeolog) [NCBI Gene 380441], WNT1 (Wnt family member 1) [NCBI Gene 7471], nes.L (nestin L homeolog) [NCBI Gene 108699393], TP53 (tumor protein p53) [NCBI Gene 7157]
- **Chemicals:** temozolomide (PubChem CID 5394), Propidium iodide (PubChem CID 4939)
- **Diseases:** Glioblastoma (MONDO:0018177)

## Full-text entities

- **Genes:** CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, ROMO1 (reactive oxygen species modulator 1) [NCBI Gene 140823] {aka C20orf52, MTGM, MTGMP, bA353C18.2}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, DNTT (DNA nucleotidylexotransferase) [NCBI Gene 1791] {aka TDT}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, WNT1 (Wnt family member 1) [NCBI Gene 7471] {aka BMND16, INT1, OI15}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, MGMT (O-6-methylguanine-DNA methyltransferase) [NCBI Gene 4255], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** cytotoxic (MESH:D064420), colorectal cancer (MESH:D015179), cell (MESH:D002292), astrocytoma (MESH:D001254), GB (MESH:D005909), brain tumour (MESH:D001932), HCE (MESH:D006734), necrotic (MESH:D009336), aggressiveness (MESH:D010554), BC (MESH:D001943), ND (MESH:C537849), Tumour (MESH:D009369), Mitochondrial Damage (MESH:D028361), pancreatic cancer (MESH:D010190), inflammatory (MESH:D007249), glioma (MESH:D005910)
- **Chemicals:** Alexa Fluor-488 (MESH:C000711379), MDA (MESH:D008315), beta-escin (MESH:D004928), Nitrite (MESH:D009573), TMZ (MESH:D000077204), MTT (MESH:C070243), haematoxylin (MESH:D006416), Penicillin (MESH:D010406), Hoechst (-), cisplatin (MESH:D002945), PI (MESH:D011419), H&amp;E (MESH:D006371), crystal violet (MESH:D005840), DMSO (MESH:D004121), 4',6'-diamidino-2-phenylindole (MESH:C007293), ROS (MESH:D017382), saponin (MESH:D012503), eosin (MESH:D004801), PFA (MESH:C003043), lipid (MESH:D008055), agarose (MESH:D012685), MitoTracker Red CMXRos (MESH:C107472), L-glutamine (MESH:D005973), GSH (MESH:D005978), CO2 (MESH:D002245), Streptomycin (MESH:D013307), NO2 - (MESH:D009585), HCOOH (MESH:C030544), paraffin (MESH:D010232), methanol (MESH:D000432), GlutaMAX (MESH:C054122), 2,7-dichlorofluorescin diacetate (MESH:C029569), 3-NT (MESH:C002744), H2O (MESH:D014867), tetrazolium (MESH:D013778)
- **Species:** Homo sapiens (human, species) [taxon 9606], Felis catus (cat, species) [taxon 9685], Aesculus hippocastanum (common horse chestnut, species) [taxon 43364], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** U87 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0022), A172 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0131)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12907738/full.md

---
Source: https://tomesphere.com/paper/PMC12907738